InfertilityCLARITYNCT07315568
Couples and Microbial Diversity
An observational study of Infertility and Transmission, run by Tampere University Hospital.
Trial summary
Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Infertility, Transmission, Infections
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 5 Jan 2026to 30 Dec 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Couples attending the Tampere University Hospital (TAUH) infertility clinic due to problems in conceiving during the past 12 months.
Who may be able to join
- Problems in conceiving the past 12 months
- Over 18 years old
- Fluent in Finnish
Who cannot join
- Needs for donated gametes (except for female homosexual couples)
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Marianne Kamaja, MD contact
About this study
Official title: COUPLES AND MICROBIAL DIVERSITY
Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments.
The study will be conducted at the Infertility Clinic of Tampere University Hospital, Tampere Finland; and will recruit 200 couples undergoing infertility investigations and treatments. Oral and genital tract samples will be collected at baseline and every six months during a two-year follow-up period. Background information will be obtained through a secure online questionnaire.
Couples who achieve pregnancy will be followed according to the CLARITY protocol until delivery, after which families will transition to the CLARITY-Baby extension study. Samples from both the newborn and parents will be collected at delivery and again at six months postpartum, accompanied by an online follow-up questionnaire completed by the parents.
Read the detailed description
Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments.
This research proposals main aim is to explore a variety of outcomes related to HPV-infection and other microbes and to evaluate how different variables of the mucosal ecosystem impacts these outcomes.
The study has three main parts:
PART 1. Describe couples' oral and genital HPV infections prevalence jointly with the other oral and genital microbial diversity in longitudinal setting.
PART 2. Investigate the role of different microbe infections and interactions in reproductive health and pregnancy success rate among couples enrolled for infertility treatments at the clinic.
PART 3. Provide information on the mother-child and father-child microbial vertical and horizontal transmission.
Study sets: We plan to recruit to a prospective cohort study 200 couples attending the Tampere University Hospital (TAUH) infertility clinic due to problems in conceiving during the past 12 months.
Samples: At recruitment (Baseline) we will take swab samples from vulva, cervix, vagina and anus, as well as saliva samples and gargle samples from oral cavity from all participating women. From the males otherwise same oral samples are taken as from the women, apart from genital samples that will be taken from the penile shaft, and additionally a semen sample is collected. The plan of infertility treatment itself is not affected and patients are treated according to routine practice guidelines. The follow-up samples are self-collected samples at 6, 12, 18 and 24 months (saliva, oral gargle, genital sample (in men genital sample is optional). With the extended CLARITY-Baby protocol at delivery the following additional samples will be collected: a breast milk from the mother, sample form the placenta and samples from the offspring (genital, saliva and oral brush sample).
Questionnaire: Background information of different behavioral and reproductive factors is collected using web-based self-completed questionnaires from all study participants at baseline. When necessary, the background information is completed using patient files. Secondary shorter questionnaires will be done at 12 months and 24 months of the CLARITY-protocol and at 6 months follow-up visit after delivery in the CLARITY-Baby Protocol.
Biological assays include: HPV genotyping, HLA typing, metagenomic sequencing, methylation analysis, and targeted sequencing.
Statistical analysis plans will vary by study objective and will include logistic regression, generalized estimating equations (GEE), ROC curve construction, and compositional methods for microbial profiling. All analyses will be conducted using STATA (STATA Corp., TX).
Schedule The study has been approved by the Wellbeing Services County of Pirkanmaa District Ethical Review Board. Recruitment will start in Janyary 2026.
Findings will support the development of prevention strategies, improved risk stratification, and innovative diagnostic and therapeutic approaches for couples to optimize the prevention and control strategies as well as improvement for infertility treatments.
- Conditions
- Infertility, Transmission, Infections
- Keywords
- Human Microbiome, HPV, Infertility, Microbial Diversity
- Medical subject headings
- Infertility, Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| CLARITY | Couples attending the Tampere University Hospital (TAUH) infertility clinic due to problems in conceiving during the past 12 months. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Risks and dynamics of different microbes and transmission among infertile couples
Oral and genital samples are sequenced for various microbes with metagenomic sequencing to detect various viral, bacterial and mycobiome infections
Measured: From enrolment to 24 month follow-up samples
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jan 2026
- Study start5 Jan 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tampere University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Karolina Louvanto, Professor, Principal investigator, Tampere University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07315568
- Sponsor's protocol ID
- R23082
- Acronym
- CLARITY
- Status last verified
- Dec 2025
- First submitted
- 18 Dec 2025
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- COUPLES AND MICROBIAL DIVERSITY
- ClinicalTrials.gov ID
- NCT07315568
- Acronym / sponsor ID
- CLARITY / R23082
- Conditions
- Infertility, Transmission, Infections
- Keywords
- Human Microbiome, HPV, Infertility, Microbial Diversity
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Tampere University HospitalUniversity, hospital or other
- Study start
- 5 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Dec 2031 (estimated)
- First posted
- 2 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments.
The study will be conducted at the Infertility Clinic of Tampere University Hospital, Tampere Finland; and will recruit 200 couples undergoing infertility investigations and treatments. Oral and genital tract samples will be collected at baseline and every six months during a two-year follow-up period. Background information will be obtained through a secure online questionnaire.
Couples who achieve pregnancy will be followed according to the CLARITY protocol until delivery, after which families will transition to the CLARITY-Baby extension study. Samples from both the newborn and parents will be collected at delivery and again at six months postpartum, accompanied by an online follow-up questionnaire completed by the parents.
Detailed description
Couples and Microbial Diversity (CLARITY) - study is a prospective study that investigates the risks and dynamics of different microbes and transmission among couples to optimize the prevention and control strategies as well as improvement for infertility treatments.
This research proposals main aim is to explore a variety of outcomes related to HPV-infection and other microbes and to evaluate how different variables of the mucosal ecosystem impacts these outcomes.
The study has three main parts:
PART 1. Describe couples' oral and genital HPV infections prevalence jointly with the other oral and genital microbial diversity in longitudinal setting.
PART 2. Investigate the role of different microbe infections and interactions in reproductive health and pregnancy success rate among couples enrolled for infertility treatments at the clinic.
PART 3. Provide information on the mother-child and father-child microbial vertical and horizontal transmission.
Study sets: We plan to recruit to a prospective cohort study 200 couples attending the Tampere University Hospital (TAUH) infertility clinic due to problems in conceiving during the past 12 months.
Samples: At recruitment (Baseline) we will take swab samples from vulva, cervix, vagina and anus, as well as saliva samples and gargle samples from oral cavity from all participating women. From the males otherwise same oral samples are taken as from the women, apart from genital samples that will be taken from the penile shaft, and additionally a semen sample is collected. The plan of infertility treatment itself is not affected and patients are treated according to routine practice guidelines. The follow-up samples are self-collected samples at 6, 12, 18 and 24 months (saliva, oral gargle, genital sample (in men genital sample is optional). With the extended CLARITY-Baby protocol at delivery the following additional samples will be collected: a breast milk from the mother, sample form the placenta and samples from the offspring (genital, saliva and oral brush sample).
Questionnaire: Background information of different behavioral and reproductive factors is collected using web-based self-completed questionnaires from all study participants at baseline. When necessary, the background information is completed using patient files. Secondary shorter questionnaires will be done at 12 months and 24 months of the CLARITY-protocol and at 6 months follow-up visit after delivery in the CLARITY-Baby Protocol.
Biological assays include: HPV genotyping, HLA typing, metagenomic sequencing, methylation analysis, and targeted sequencing.
Statistical analysis plans will vary by study objective and will include logistic regression, generalized estimating equations (GEE), ROC curve construction, and compositional methods for microbial profiling. All analyses will be conducted using STATA (STATA Corp., TX).
Schedule The study has been approved by the Wellbeing Services County of Pirkanmaa District Ethical Review Board. Recruitment will start in Janyary 2026.
Findings will support the development of prevention strategies, improved risk stratification, and innovative diagnostic and therapeutic approaches for couples to optimize the prevention and control strategies as well as improvement for infertility treatments.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CLARITY | – | –Couples attending the Tampere University Hospital (TAUH) infertility clinic due to problems in conceiving during the past 12 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Couples attending the Tampere University Hospital (TAUH) infertility clinic due to problems in conceiving during the past 12 months.
Key inclusion criteria (3 listed)
- Problems in conceiving the past 12 months
- Over 18 years old
- Fluent in Finnish
Key exclusion criteria (1 listed)
- Needs for donated gametes (except for female homosexual couples)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Risks and dynamics of different microbes and transmission among infertile couples
Time frame: From enrolment to 24 month follow-up samples
Oral and genital samples are sequenced for various microbes with metagenomic sequencing to detect various viral, bacterial and mycobiome infections
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Individual participant dataSharing planned: Yes. IPD that underlie results in a publication
Related trials for Infertility
RecruitingPhase 3
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Infertility
Active, not recruitingObservational study
Fresh Versus Vitrified-Warmed Donor Oocytes: Embryological and Clinical Outcomes
Infertility, Donor Oocyte Assisted Reproduction
RecruitingObservational study
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Active, not recruiting
Automation of the In Vitro Fertilization Laboratory
Infertility, ART
Not yet recruiting
Implementing IVM for Fertility Treatment in Clinical Practice
Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marianne Kamaja, MD contact
Karolina Louvanto, Professor principal investigator
Tampere University
Questions about this trial
What is this clinical trial studying?
An observational study of Infertility and Transmission, run by Tampere University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Karolina Louvanto, Professor (+358504713838, karolina.louvanto@tuni.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Risks and dynamics of different microbes and transmission among infertile couples (time frame: From enrolment to 24 month follow-up samples). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.